ADVA launches world’s first optical transport solution with post-quantum cryptography
8.7.2021 10:00:00 EEST | Business Wire | Press release
ADVA (FSE: ADV) today launched the industry’s first optical transport solution secured by post-quantum cryptography (PQC). The FSP 3000 ConnectGuard™ optical encryption solution now protects data against cyberattacks from quantum computers that could break today’s cryptographic algorithms. The quantum-safe security technology relies on a hybrid key exchange system, combining PQC algorithms with classical encryption methods. Built for crypto-agility, the solution is ready for software updates in the future, ensuring it delivers the most robust network protection now and for decades to come.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210708005050/en/
ADVA’s FSP 3000 ConnectGuard™ encryption solution now protects data against cyberattacks from quantum computers (Photo: Business Wire)
“Our market-first FSP 3000 quantum-safe ConnectGuard™ encryption technology answers the urgent threat posed by quantum computers and gives organizations a way to safeguard their networks before the danger materializes. Our customers’ data will be fully protected even from cybercriminals’ intent on harvesting information so that they can store it today and exploit it tomorrow,” said Christoph Glingener, CTO, ADVA. “We’re providing long-term security for data in motion. What’s more, our solution is ready to be upgraded later to comply with emerging specifications, including the NIST’s PQC standardization competition.”
As recommended by leading cybersecurity authorities, the PQC-protected ADVA FSP 3000 ConnectGuard™ encryption solution utilizes the traditional Diffie-Hellman protocol and combines it with a newly developed algorithm based on the quantum-safe McEliece cryptosystem. This enables it to produce encryption keys that even powerful quantum computers will be unable to crack. As well as delivering data integrity with quantum-safe Layer 1 AES-256 protection, the ADVA FSP 3000 ConnectGuard™ encryption solution ensures minimal impact on latency, throughput and performance. The technology is also easily deployable over long-haul and multi-operator links.
“Organizations everywhere have woken up to the security threat that quantum computing represents. With many experts anticipating powerful commercially available quantum computers in the next decade, it’s now widely understood that the danger is very real and the stakes are enormously high. That’s why we’ve invested so much time and energy into developing the world’s first transport solution ready for the challenges ahead,” commented Jörg-Peter Elbers, SVP, advanced technology, ADVA. “By integrating PQC security into our FSP 3000 ConnectGuard™ optical encryption solution, we’re empowering our customers to protect their networks today against tomorrow’s threats. Our solution is easily deployable and only requires end-point access. What’s more, it works over any distance and in any optical transport network.”
Watch this Tech Cam video for more information: https://youtu.be/4fs6zV5FnME.
Further details are also available in these slides: https://adva.li/pqc-slides.
A supporting solution brief can be downloaded here: https://adva.li/pqc-solution-brief.
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.
Published by:
ADVA Optical Networking SE, Munich, Germany
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210708005050/en/
Contact information
For press:
Gareth Spence
t +44 1904 699 358
public-relations@adva.com
For investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@adva.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
RS2 Financial Services GmbH Selected to Participate in ECB Digital Euro Pilot14.7.2026 15:22:00 EEST | Press release
RS2 Financial Services GmbH, an electronic money institution supervised by BaFin and part of the RS2 Group, operating under its innovation brand Beyond by RS2, has been selected to participate as an acquiring payment service provider in the Eurosystem’s digital euro pilot. The pilot marks the transition from technical preparation to practical validation, testing how a potential digital euro could function in everyday consumer and merchant payment scenarios. According to the official announcement of the European Central Bank, RS2 Financial Services GmbH is one of 36 payment service providers selected to participate in the programme. The participating organisations reflect a range of institution sizes, business models and markets across the euro area. RS2 Financial Services GmbH will contribute its expertise in acquiring and merchant payments to the pilot, leveraging the RS2 Group’s cloud-native payment technology and technical capabilities to support pilot execution. The Eurosystem plan
Dompé Doses First Patient in Phase 3 Study of Cenegermin-bkbj in NAION14.7.2026 15:00:00 EEST | Press release
Dompé, a biopharmaceutical company with operations in Italy and the US, announced the first patient has been enrolled in a Phase 3 study of cenegermin-bkbj for the treatment of non-arteritic anterior ischemic neuropathy (NAION). Involving more than 130 centers globally, the Phase 3 trial, “Galassia-NAION-301” is a multicenter, double-blind study comparing cenegermin-bkbj against placebo in improving vision loss caused by NAION. “Our NGF R&D program continues to accelerate with our third clinical study of 2026,” said Marcello Allegretti, Chief Scientific Officer at Dompé. “Dosing the first patient in our NAION trial marks a critical step in our mission to unlock the full potential of NGF. By advancing our proprietary intranasal NGF in clinical investigation, we are taking a bold, non-invasive approach that bypasses the blood-brain barrier and has the potential to redefine the standard of care.” NAION refers to a loss of blood flow to the optic nerve which causes rapid vision loss that u
Esri to Debut the Power of Where Collection at 2026 Esri User Conference14.7.2026 15:00:00 EEST | Press release
Esri, the global leader in location intelligence, will debut the Power of Where Collection at the 2026 Esri User Conference in July. The collection builds on the ideas introduced in The Power of Where: A Geographic Approach to the World's Greatest Challenges, by Esri president Jack Dangermond, published in 2024. The new collection expands these foundational concepts into focused, real-world applications that demonstrate the growing impact of geographic information system (GIS) technology. The first two other books starting the collection are Geowater: A Geographic Approach to Water Data and Forecasting and Parcels: How Property Shapes Geography. Together, these titles illustrate how spatial thinking and GIS are transforming how organizations understand systems, manage resources, and plan for the future. The Power of Where Collection reflects Esri’s ongoing commitment to helping organizations make smarter, more informed decisions across industries—on topics ranging from water sustainabi
Esri Helps Bring Up-to-Date Road Closure Information to Google Maps and Waze14.7.2026 15:00:00 EEST | Press release
Esri has expanded its Community Maps Program, enabling road closure data to be shared with Google Maps and Waze. The Road Closures solution, in Esri's ArcGIS platform, was introduced last year as a way for users to easily share road closure updates directly with popular consumer mapping providers so they can update their maps with this important information. The solution aimed to bridge the gap between government agencies managing timely road updates and the public, who rely on mapping apps for real-time navigation. Over 100 communities around the United States and other countries are actively sharing their road closure information. ArcGIS users can now easily share that same authoritative data with Google Maps and Waze via the Waze for Cities program. "For over a year, we've been working with dozens of our local government users to share their road closure information with our initial consumer mapping partners, Apple Maps and TomTom," said Deane Kensok, chief technology officer for Ar
CE-IVDR Mark for Hologic’s Aptima ® HPV Test Expanded to Include Self-Collected Sample Claim in Cervical Cancer Screening14.7.2026 15:00:00 EEST | Press release
Hologic, Inc. announced today that its Aptima® HPV Assay received an expanded CE-IVDR marking in the European Union and the UK and is now approved for self-collected vaginal samples using the Aptima Multitest Specimen Collection Kit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260714358586/en/ Hologic’s Aptima® HPV Assay and Aptima Multitest Specimen Collection Kit Cervical cancer is the fourth most common cancer in women but is largely preventable through HPV vaccination and regular screening.1 Evidence shows that organized screening and early detection reduces deaths from cervical cancer, with mortality reduction rates in Europe ranging from 41% to 92%.2 However, even in countries with an established cervical screening program, screening participation rates vary widely, from 25% to 80%, with some showing stagnation or decline in recent years.3 “Despite the benefits of cervical cancer screening, there are still barriers
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom